The short version of quality control fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-12-02 and is reviewed periodically as new material appears.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
=== Prosecution in the United States === Following his capture Noriega was transferred to a cell in the Miami federal courthouse, where he was arraigned on the ten charges which the Miami grand jury had returned two years earlier. The trial was delayed until September 1991 over whether Noriega could be tried after his detention as a prisoner of war, the admissibility of evidence and witnesses, and how to pay for Noriega's legal defense. The trial ended in April 1992, when Noriega was convicted on eight of the ten charges of drug trafficking, racketeering, and money laundering. On July 10, 1992, Noriega was sentenced to 40 years in prison. In pre-trial proceedings, the government stated that Noriega had received $322,000 from the U.S. Army and the CIA. Noriega insisted that he had in fact been paid close to $10,000,000, and that he should be allowed to testify about the work he had done for the U.S. government. The district court held that information about the operations in which Noriega had played a part supposedly in return for payment from the U.S. was not relevant to his defense. It ruled that "the tendency of such evidence to confuse the issues before the jury substantially outweighed any probative value it might have had." One of the witnesses in the trial was Carlton, who had previously flown shipments of drugs for Noriega. Information about Noriega's connections to the CIA, including his alleged contact with Bush, were kept out of the trial. After the trial, Noriega appealed this exclusionary ruling by the judge to the Eleventh Circuit Court of Appeals.
== Further reading == Maheshwari, Saurabh; Ingole, Dilip; Chatterjee, Samar; Rajesh, Uddandam; Anand, Varun (2021). "A case report of achondrogenesis type II (Langer-Saldino achondrogenesis)". Egyptian Journal of Radiology and Nuclear Medicine. 52 (1) 113. doi:10.1186/s43055-021-00479-0. ISSN 2090-4762. Kobayashi, Yukari; Ito, Yuki; Taniguchi, Kosuke; Harada, Kana; Yamamura, Michihiro; Sato, Taisuke; Takahashi, Ken; Kawame, Hiroshi; Hata, Kenichiro; Samura, Osamu; Okamoto, Aikou (2022-11-15). "Novel missense COL2A1 variant in a fetus with achondrogenesis type II". Human Genome Variation. 9 (1). Springer Science and Business Media LLC: 40. doi:10.1038/s41439-022-00218-5. ISSN 2054-345X. PMC 9663423. PMID 36376277.
== References == McGraw-Hill Encyclopedia of Science & Technology (10th ed.). New York: McGraw-Hill. 2007. ISBN 978-0-07-144143-8. Serway, Raymond A.; Moses, Clement J.; Moyer, Curt A. (1989), Modern Physics, Fort Worth: Harcourt Brace Jovanovich, ISBN 0-03-004844-3 Simmons, George F. (1972), Differential Equations with Applications and Historical Notes, New York: McGraw-Hill, LCCN 75173716
A change in the difference in isotopic composition of precipitation on the two sides of a mountain can be used to infer the magnitude of the rain shadow effect. In one such study, an isotope enrichment was observed in smectite on the east side of the Sierra Nevada in California from mid-Miocene to late Pliocene, suggesting a decrease in elevation during this period. Another study found δDs around −140‰ in muscovite in the North America Cordillera during the early Eocene, which would suggest an elevation 1km higher than today at the time. In addition to hydrous minerals, hydrogen isotopes in biomarkers such as leaf waxes have also been developed for paleoaltimetry studies. The δD lapse rate in leaf waxes (−21‰/km) falls in the range of meteoric water observations. As an example study, leaf wax δD data has been used to confirm hydrous mineral paleoaltimetry for the high elevation of the Sierra Nevada during the Eocene.
Sources: en.wikipedia.org
=== Founding === In the early 1950s, Lovell Corporation won a contract from the U.S. Army Chemical Engineers to develop and manufacture membrane filtering devices used to separate the molecular components of fluid samples. When the membranes were declassified in 1953 and offered for commercial use, Jack Bush, son of Vannevar Bush and a Lovell employee, bought the company's technology for $200,000 and established the Millipore Filter Company. Bush coined the word millipore to refer to the numerous tiny openings in the microporous membrane product. The term "millipore", originally a trademark, has since come into generic use, referring to any of several filters, made from cellulose acetate membranes, capable of removing very small particles. Later the company changed its name to Millipore Corporation to reflect its growing range of products. In 2010, Merck KGaA the world's oldest chemical and pharmaceutical company, acquired Millipore Corporation to form EMD Millipore.
As field rations are intended to last long, the packaging they are stored in is designed to ensure a long shelf life and prevent spoilage, while also being light and compact enough to be carried without issue. Rations are canned, vacuum-sealed, or freeze-dried foods stored in packages to prevent leakage or spoilage, commonly retort pouches, boxes, or cases. These containers are preferably easy to open anywhere, though some may require specific tools that are issued to soldiers or included in the ration package, such as the American P-38 can opener or Australian field ration eating device. Some, but not all, ration packages may be biodegradable or compostable.
Mean Absolute Relative Difference (MARD) is a standard metric used to evaluate the accuracy of continuous glucose monitoring systems, which gives the average amount a CGM sensor reading varies from the actual blood glucose. It is calculated by taking the average of the absolute relative differences between the glucose readings reported by the CGM system and corresponding reference measurements, typically obtained through laboratory analysis or blood glucose meters. A lower MARD value indicates greater accuracy, and it is commonly used in clinical research and regulatory evaluations to compare the performance of different CGM devices. It is also of note that MARD percentages can vary by person, even while using the same device. The accuracy of Dexcom CGM systems has steadily improved over time, as reflected in declining MARD values across successive generations. The original Dexcom STS, released in 2006, had a MARD of approximately 20.3%, while the Dexcom Seven, introduced in 2007, reduced this to around 17%. The Seven Plus had a slightly lower MARD of 16%. The G4 Platinum, launched in 2012, further improved accuracy with a MARD of 13.9%, followed by the G5 Mobile in 2015, which achieved 9%—the first Dexcom system to reach single-digit accuracy. in some users, however it also was found to be as high as 15%. The Dexcom G6, released in 2018, was similarly marketed with a MARD of 9%, although some studies found values exceeding 12% in certain individuals.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.